Kumar will take over the reins at the Toronto-based cannabis company’s science and innovation division where he will oversee all science initiatives.
Boasting more than 25 years of experience in the pharmaceutical industry, Dr Kumar is a seasoned executive who has international experience in Europe, Asia and North America.
"We are incredibly excited to welcome Dr. Kumar to TGOD. He is a proven and seasoned senior executive with extensive international pharmaceutical experience in developing innovative and novel products with some of the world's largest pharmaceutical companies," said CEO Brian Athaide in a statement.
Dr Kumar previously held a number of senior roles at the pharmaceutical giant GlaxoSmithKline where his posts included vice-president for research and development operations as well as for business development and classic brands.
On top of this, Dr Kumar played a key role in building GSK’s research and development capability in Canada. He also executed a $150 million spin-out of GSK’s vaccines research and development unit to create the Neomed Biologics and Vaccines Centre of Excellence in Montreal.
In addition to his time at GSK, Dr Kumar also served as managing director of Apotex India, the Canadian pharmaceutical company Apotex’s largest investment outside of Canada.
Dr Kumar holds a Doctor of Philosophy from the University of Bath in the UK and a Bachelor of Pharmacy (Honors) from the University of Cardiff in the UK.
The Green Organic Dutchman shares nudged up 1% to finish at C$2.98 on Wednesday.
Contact Ellen Kelleher at [email protected]